Novocure-Zai announce MAA approval for Optune to treat GBM patients
Date: 2020-05-15   Author: Saipriya Iyer  Category: #news

Novocure-Zai announce MAA approval for Optune to treat GBM patients

Novocure and Zai Lab Ltd. have recently announced the MAA (Marketing Authorization Application) approval from the China NMPA (National Medical Products Administration). The approval has been given for the use of Optune, in combination with temozolomide, to treat newly diagnosed GBM (glioblastoma) patients. It will also be used as a monotherapy for patients suffering from recurrent GBM. Optune is the 1st treatment for GBM that has been approved in over 15 years in China.

According to Dr. Samantha Du, Zai Lab’s CEO, Chairperson, and Founder, the recent approval is a significant treatment advancement for GBM patients in China and an important milestone for the company. Optune has previously been granted with the Innovative Medical Device Designation. It highlights the importance and differentiation of this novel treatment for patients with GBM. The company appreciates NMPA for this thorough and rapid assessment of the application of Optune, which will help serve high unmet medical needs. Dr. Du further stated that the company is looking forward to working with Novocure, to leverage Tumor Treating Fields and treat several cancer indications, including GBM.

William Doyle, Executive Chairman of Novocure, stated that the company is focusing on the commercialization and development of Tumor Treating Fields to increase the survival rate of several aggressive cancers. He also expressed appreciation towards their partner, Zai Lab, for collectively working to obtain Optune approval in Greater China.

Tumor Treating Fields therapy is delivered by Optune to the tumor region. It has been used to treat over 15,000 GBM patients to date, globally. The therapy has been approved by the FDA for the treatment of MPM (malignant pleural mesothelioma), which is expected to be the next Marketing Authorization Application filed with the China NMPA. It is also under Phase 3 pivotal trials to treat ovarian cancer, pancreatic cancer, non-small cell lung cancer, and brain metastases, and in Phase 2 pilot trials to treat gastric cancer and liver cancer. In China, over 1.5 million patients are diagnosed with gastric, ovarian, non-small cell lung, and pancreatic cancers, collectively in a year.

Source credit:https://www.businesswire.com/news/home/20200513005458/en/China-NMPA-Approves-Optune%C2%AE-Treatment-Newly-Diagnosed



About Author


Saipriya Iyer

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

More from Saipriya


Post Recommendents

Global Fire Doors Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast
Author: Ashwin Naphade

Market Study Report, LLC adds latest research report on ' Fire Doors Market', which delivers a comprehensive study on current industry trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrates its...


Global Honing Machines Market Analysis, Growth, Size, Demand & Forecast 2020-2026
Author: Ashwin Naphade

The ' Honing Machines market' study added by Market Study Report, LLC, enumerates an in-depth analysis of the powerful trends prevailing in the industry. This study also encompasses valuable information relating to the profitability prospe...


Arc Fault Circuit Interrupter (AFCI) Market Report by Growth Enablers, Geography, Restraints and Trends – Global Forecast To 2026
Author: Ashwin Naphade

The ' Arc Fault Circuit Interrupter (AFCI) market' study now available with Market Study Report, LLC, is a systematic detailing of the potential factors driving the revenue statistics of this industry. Key data documented in the study incl...